Woodline Partners LP filed an amended Schedule 13G reporting beneficial ownership of 5,455,355 shares of SAB Biotherapeutics, Inc. common stock, including shares issuable upon conversion of preferred stock underlying warrants. This represents 6.8% of the outstanding common stock.
The position consists of 1,180,355 common shares, plus 2,850,000 shares issuable from Series B Preferred Stock underlying Enrollment Warrants and 1,425,000 shares issuable from Series B Preferred Stock underlying Data Release Warrants, all held for Woodline Master Fund LP. The percentage is based on 76,464,094 common shares outstanding as of May 6, 2026. Woodline reports sole voting and dispositive power over the 5,455,355 shares, with the Woodline Fund entitled to dividends and sale proceeds.
Positive
None.
Negative
None.
Key Figures
Beneficial ownership:5,455,355 sharesOwnership percentage:6.8%Common shares held:1,180,355 shares+3 more
6 metrics
Beneficial ownership5,455,355 sharesTotal SAB Biotherapeutics common shares beneficially owned by Woodline Partners
Ownership percentage6.8%Portion of SAB Biotherapeutics common stock beneficially owned by Woodline Partners
Common shares held1,180,355 sharesOutstanding SAB Biotherapeutics common stock held by Woodline-related fund
Shares via Enrollment Warrants2,850,000 sharesShares issuable upon conversion of Series B Preferred Stock underlying Enrollment Warrants
Shares via Data Release Warrants1,425,000 sharesShares issuable upon conversion of Series B Preferred Stock underlying Data Release Warrants
Shares outstanding baseline76,464,094 sharesSAB Biotherapeutics common shares outstanding as of May 6, 2026
Key Terms
Series B Preferred Stock, Enrollment Warrants, Data Release Warrants, beneficial owner
4 terms
Series B Preferred Stockfinancial
"shares of Common Stock issuable upon conversion of Series B preferred stock underlying"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Enrollment Warrantsfinancial
"Series B preferred stock underlying 28,500 enrollment warrants (the "Enrollment Warrants")"
Data Release Warrantsfinancial
"Series B Preferred Stock underlying 14,250 data release warrants (the "Data Release Warrants")"
beneficial ownerfinancial
"not be construed as an admission that any of the foregoing persons ... is ... the beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
FAQ
What percentage of SAB Biotherapeutics (SABS) does Woodline Partners report owning?
Woodline Partners reports beneficial ownership of 6.8% of SAB Biotherapeutics’ common stock. This percentage is based on 76,464,094 shares outstanding as of May 6, 2026, and includes shares issuable upon conversion of Series B Preferred Stock tied to warrants.
How many SAB Biotherapeutics (SABS) shares does Woodline Partners beneficially own?
Woodline Partners reports beneficial ownership of 5,455,355 shares of SAB Biotherapeutics common stock. This total includes both 1,180,355 currently outstanding shares and additional shares issuable upon conversion of Series B Preferred Stock linked to Enrollment and Data Release Warrants.
What is the structure of Woodline’s SAB Biotherapeutics (SABS) position?
Woodline’s position includes 1,180,355 common shares, 2,850,000 shares issuable from Series B Preferred Stock via Enrollment Warrants, and 1,425,000 shares issuable from Series B Preferred Stock via Data Release Warrants, for a total beneficial ownership of 5,455,355 shares.
Does Woodline Partners have voting and dispositive power over its SAB Biotherapeutics (SABS) shares?
Yes. Woodline Partners reports sole voting power and sole dispositive power over 5,455,355 SAB Biotherapeutics shares. No shared voting or shared dispositive power is reported for this stake held for Woodline Master Fund LP.
What share count did Woodline use to calculate its 6.8% ownership of SAB Biotherapeutics (SABS)?
The 6.8% ownership is calculated using 76,464,094 SAB Biotherapeutics common shares outstanding as of May 6, 2026. This share count comes from the company’s Form 10-Q for the quarter ended March 31, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
SAB Biotherapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
78397T202
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
78397T202
1
Names of Reporting Persons
Woodline Partners LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
5,455,355.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,455,355.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,455,355.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.8 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: Consists of (i) 1,180,355 shares of Common Stock (as defined in Item 2(a)), (ii) 2,850,000 shares of Common Stock issuable upon conversion of 28,500 shares of Series B preferred stock (the "Series B Preferred Stock") underlying 28,500 enrollment warrants (the "Enrollment Warrants") and (iii) 1,425,000 shares of Common Stock issuable upon conversion of 14,250 shares of Series B Preferred Stock underlying 14,250 data release warrants (the "Data Release Warrants").
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
SAB Biotherapeutics, Inc.
(b)
Address of issuer's principal executive offices:
777 W 41st St, Suite 401, Miami Beach, Florida 33140
Item 2.
(a)
Name of person filing:
This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of SAB Biotherapeutics, Inc. (the "Company"), and shares of Common Stock issuable upon the conversion of Series B Preferred Stock issuable upon the exercise of the Data Release Warrants and Enrollment Warrants, directly held by the Woodline Fund.
The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)
Citizenship:
Woodline Partners is a Delaware limited partnership.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
78397T202
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 76,464,094 shares of Common Stock outstanding as of May 6, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026, and assumes the conversion of the Series B Preferred Stock issuable upon the exercise of the Enrollment Warrants and the Data Release Warrants held by the Woodline Fund.
(b)
Percent of class:
6.8%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Woodline Fund has right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Woodline Partners LP
Signature:
/s/ Erin Mullen
Name/Title:
By: Erin Mullen, General Counsel & Chief Compliance Officer
